-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Benzinga·05/13/2026 18:48:30
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $26 to $20.